Charlotte E. Vollenbrock

Charlotte E. Vollenbrock

Auto-generated profile, based on publicly available information

Charlotte E. Vollenbrock

University Medical Center Groningen, Endocrinology, University of Groningen, Groningen, Groningen, The Netherlands

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2022 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
PDF file
RVRita Delphine Maiko Varkevisser
Rita Delphine Maiko Varkevisser
EBErwin Birnie
Erwin Birnie
CVCharlotte E Vollenbrock
Charlotte E Vollenbrock
DMDick Mul
Dick Mul
PDPeter Van Dijk
Peter Van Dijk
HAHenk-Jan Aanstoot
Henk-Jan Aanstoot
Introduction Cardiovascular disease (CVD) is the leading cause of mortality in individuals with type 1 diabetes mellitus (T1DM). Cardiovascular risk management is therefore essential in the management of individuals with T1DM. This study describes the performance of lipid and blood pressure management in individuals with T1DM using three guidelines. Research design and methods Individuals ≥18 years with T1DM, treated with insulin for ≥1 year, visiting Diabeter or the University Medical Center Groningen between January 1, 2018 and December 31, 2018, were included. Lipid and blood pressure management were examined using the Dutch, American Diabetes Association (ADA) and National Institute for Health and Care Excellence (NICE) guidelines. Concordance of recommended and prescribed lipid-lowering (LLM) or antihypertensive medication (AHM) was assessed per guideline and 10-year age groups. Achievement of treatment targets was assessed for those prescribed medication. Results A total of 1855 individuals with T1DM were included. LLM and AHM was prescribed in 19% and 17%, respectively. In individuals recommended LLM, this was prescribed in 22%–46% according to Dutch, ADA or NICE guideline recommendations. For individuals recommended AHM, this was prescribed in 52%–75%. Recommended and actual prescription of LLM and AHM increased over age for all three guidelines. However, discordance between treatment recommendation and medication prescribed was higher in younger, compared with older, age groups. Low-density lipoprotein-cholesterol targets were achieved by 50% (without CVD) and 31% (with CVD) of those prescribed LLM. The blood pressure target was achieved by 46% of those prescribed AHM. Conclusion This study suggests that there is undertreatment of lipid and blood pressure according to guideline recommendations, particularly in younger age groups. Treatment targets are not met by most individuals prescribed medication, while guidelines recommendations differ considerably. We recommend to investigate the factors influencing undertreatment of lipid and blood pressure management in individuals with T1DM.

4 December 2022 in Diabetic Medicine
Verified
Journal Article
Open access
CVCharlotte E. Vollenbrock
Charlotte E. Vollenbrock
DMDick Mul
Dick Mul
PDPim Dekker
Pim Dekker
EBErwin Birnie
Erwin Birnie
MVMartine M. C. de Vries‐Velraeds
Martine M. C. de Vries‐Velraeds
BWBruce H.R. Wolffenbuttel
Bruce H.R. Wolffenbuttel
Aims: This study aims to evaluate the stability of C‐peptide over time and to compare fasting C‐peptide and C‐peptide response after mixed‐meal tolerance test (MMTT) at T90 or T120 with C‐peptide area under the curve (AUC) in long‐standing type 1 diabetes.Methods: We included 607 type 1 diabetes individuals with diabetes duration >5 years. C‐peptide concentrations (ultrasensitive assay) were collected in the fasting state, and in a subpopulation after MMTT (T0, just prior to, T30‐T60‐T90‐T120, 30–120 min after ingestion of mixed‐meal) (n = 168). Fasting C‐peptide concentrations (in n = 535) at Year 0 and Year 1 were compared. The clinical determinants associated with residual C‐peptide secretion and the correspondence of C‐peptide at MMTT T90 / T120 and total AUC were assessed.Results: A total of 153 participants (25%) had detectable fasting serum C‐peptide (i.e ≥ 3.8 pmol/L). Fasting C‐peptide was significantly lower at Year 1 (p < 0.001, effect size = −0.16). Participants with higher fasting C‐peptide had a higher age at diagnosis and shorter disease duration and were less frequently insulin pump users. Overall, 109 of 168 (65%) participants had both non‐detectable fasting and post‐meal serum C‐peptide concentrations. The T90 and T120 C‐peptide values at MMTT were concordant with total AUC. In 17 (10%) individuals, C‐peptide was only detectable at MMTT and not in the fasting state.Conclusions: Stimulated C‐peptide was detectable in an additional 10% of individuals compared with fasting in individuals with >5 years of diabetes duration. T90 and T120 MMTT measurements showed good concordance with the MMTT total AUC. Overall, there was a decrease of C‐peptide at 1‐year follow‐up.

6 January 2022 in Diabetic Medicine
Verified
Journal Article
Open access
PDF file
KLKitty de Leur
Kitty de Leur
CVCharlotte Vollenbrock
Charlotte Vollenbrock
PDPim Dekker
Pim Dekker
MVMartine de Vries
Martine de Vries
EBErwin Birnie
Erwin Birnie
LBLianne Boesten
Lianne Boesten
Introduction: C‐peptide is an important marker to assess residual insulin production in individuals with type 1 diabetes (T1D). The accuracy and detection limits of C‐peptide assays are important to detect C‐peptide microsecretion and to reliably observe changes over time in these people. We compared and verified two commercially available assays able to measure C‐peptide in the picomolar range.Methods: The ultrasensitive Mercodia enzyme‐linked immunosorbent C‐peptide assay (ELISA) was compared with the Beckman immunoradiometric assay (IRMA) for C‐peptide, assessing reproducibility (coefficient of variation [CV]), limit of blank (LoB), limit of detection (LoD) and limit of quantitation (LoQ).Results: For both assays within‐run and between‐run variation were high at the low (around the detection limit) C‐peptide concentration range, with CVs of around 40%. LoB values for the ultrasensitive ELISA and the IRMA were 1.3 and 0.16 pmol/L respectively. LoD values were 2.4 and 0.54 pmol/L respectively. LoQ values were 9.7 and 3.8 pmol/L respectively. Only the IRMA met the specifications claimed by the manufacturer.Conclusions: The IRMA provided the lowest threshold for quantification of serum C‐peptide. LoQ of commercially available assays should be established in‐house before applying them in research studies and clinical trials in which low C‐peptide levels have clinical or scientific relevance.

19 June 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
HAHenk-Jan Aanstoot
Henk-Jan Aanstoot
RVRita D M Varkevisser
Rita D M Varkevisser
DMDick Mul
Dick Mul
PDPim Dekker
Pim Dekker
EBErwin Birnie
Erwin Birnie
MKMelanie M van der Klauw
Melanie M van der Klauw
Purpose The ‘Biomarkers of heterogeneity in type 1 diabetes’ study cohort was set up to identify genetic, physiological and psychosocial factors explaining the observed heterogeneity in disease progression and the development of complications in people with long-standing type 1 diabetes (T1D). Participants Data and samples were collected in two subsets. A prospective cohort of 611 participants aged ≥16 years with ≥5 years T1D duration from four Dutch Diabetes clinics between 2016 and 2021 (median age 32 years; median diabetes duration 12 years; 59% female; mean glycated haemoglobin (HbA1c) 61 mmol/mol (7.7%); 61% on insulin pump; 23% on continuous glucose monitoring (CGM)). Physical assessments were performed, blood and urine samples were collected, and participants completed questionnaires. A subgroup of participants underwent mixed-meal tolerance tests (MMTTs) at baseline (n=169) and at 1-year follow-up (n=104). Genetic data and linkage to medical and administrative records were also available. A second cross-sectional cohort included participants with ≥35 years of T1D duration (currently n=160; median age 64 years; median diabetes duration 45 years; 45% female; mean HbA1c 58 mmol/mol (7.4%); 51% on insulin pump; 83% on CGM), recruited from five centres and measurements, samples and 5-year retrospective data were collected. Findings to date Stimulated residual C-peptide was detectable in an additional 10% of individuals compared with fasting residual C-peptide secretion. MMTT measurements at 90 min and 120 min showed good concordance with the MMTT total area under the curve. An overall decrease of C-peptide at 1-year follow-up was observed. Fasting residual C-peptide secretion is associated with a decreased risk of impaired awareness of hypoglycaemia. Future plans Research groups are invited to consider the use of these data and the sample collection. Future work will include additional hormones, beta-cell-directed autoimmunity, specific immune markers, microRNAs, metabolomics and gene expression data, combined with glucometrics, anthropometric and clinical data, and additional markers of residual beta-cell function. Trial registration number NCT04977635.

16 January 2026 in BMJ Open Diabetes Research & Care
Verified
Journal Article
Open access
CVCharlotte E Vollenbrock
Charlotte E Vollenbrock
DRDelnaz Roshandel
Delnaz Roshandel
KLKristine E Lee
Kristine E Lee
BKBarbara E Klein
Barbara E Klein
DMDick Mul
Dick Mul
DGDCCT/EDIC Research Group
DCCT/EDIC Research Group
Introduction: Type 1 diabetes is an autoimmune disease with a strong genetic basis. The aim of this study was to identify additional single-nucleotide polymorphisms (SNPs) for type 1 diabetes age at diagnosis and to replicate previously identified loci. Research design and methods: Meta genome-wide association studies of age at diagnosis from eight cohorts (n=5910 in total) were performed in three models. Model 1 was age at diagnosis with no covariates. Model 2 was age at diagnosis adjusted for DR3/DR4 genotype categories. Model 3 was similar to model 2, including the most significant SNP from model 2 (coded additively). Models 1 and 2 were also performed for major histocompatibility complex (MHC) imputed data. In addition, we tested previously identified loci for age at diagnosis and type 1 diabetes risk for association with age at diagnosis in model 1. Results: In model 1, we identified a genome-wide significant locus (rs2856721, p=3.3×10 −11 ) in the MHC region whose effect was attenuated in model 2 (p=0.03). In model 2, we identified another locus in the MHC region, rs76730244, p=4.9×10 −9 , which was associated with age at diagnosis adjusted for DR3/DR4 genotypes. Model 3 and analysis of the MHC region did not reveal novel loci. Among 14 previously identified SNPs for age at diagnosis, 6 were confirmed; in addition, 11 out of 78 non-HLA loci for type 1 diabetes risk were associated with age at diagnosis. Conclusions: We identified rs76730244 in the MHC region for age at diagnosis of type 1 diabetes, which was independent of the HLA-DR3/DR4 genotype categories. We also confirmed 6 previously identified SNPs and showed that 11 non-HLA loci for type 1 diabetes risk are associated with age at diagnosis.

21 August 2023 in medRxiv
Verified
Preprint
Open access
PDF file
DMDick Mul
Dick Mul
RVRita D.M. Varkevisser
Rita D.M. Varkevisser
HAHenk-Jan Aanstoot
Henk-Jan Aanstoot
PDPim Dekker
Pim Dekker
EBErwin Birnie
Erwin Birnie
MKMelanie M. van der Klauw
Melanie M. van der Klauw
Purpose The ‘Biomarkers of heterogeneity in type 1 diabetes’ study cohort was set up to identify genetic, physiological and psychosocial factors explaining the observed heterogeneity in disease progression and the development of complications in people with long-standing type 1 diabetes (T1D). Data and samples are available for new studies and collaborations. Participants Data- and samples were collected in two subsets. 1) A prospective cohort of 611 participants aged ≥16 years with ≥5 years T1D duration was recruited from four Dutch Diabetes clinics between June 2016 and March 2021. At baseline and 1- and 2-year follow-up visits, physical assessments were performed, and blood and urine samples were collected. Participants completed questionnaires about diabetes-related problems, quality of life, neuropathy and impaired awareness of hypoglycaemia at baseline and at the last follow-up visit. A subgroup of participants underwent mixed-meal tolerance tests (MMTT) at baseline (n=169) and at 1-year follow-up (n=104). Genetic data and linkage to medical and administrative records were also available. 2) A second cross-sectional cohort, aiming to include 200 participants aged ≥18 years with ≥35 years T1D duration, was recruited from 7 centres, collecting measurements and samples plus 5-year retrospective data. Findings to date Fasting residual C-peptide secretion associated with decreased risk of impaired awareness of hypoglycaemia. Stimulated residual C-peptide was detectable in an additional 10% of individuals compared with fasting residual C-peptide secretion. MMTT measurements at 90 minutes and 120 minutes showed good concordance with the MMTT total area under the curve. An overall decrease of C-peptide at 1-year follow-up was observed. Future plans Research groups are invited to consider the use of this data and sample collection. Future work will include additional hormones, beta-cell-directed autoimmunity, specific immune markers, microRNA’s, metabolomics and gene expression data, combined with glucometrics, anthropometric/clinical data and additional markers of residual beta-cell function. Strengths - The Biomarker cohort is a large longitudinal prospective cohort study with three time points, collecting biosamples and clinical data from participants with well-established and long-standing type 1 diabetes (≥5 years). - A subgroup with detailed clinical data underwent MMTT tests at two timepoints allowing further residual beta-cell marker studies. - The Biomarker and Long-Term type 1 Diabetes cohorts represent a “real-world” population, also including participants from non-academic/-specialised centres. Limitations - Despite the fact that data and biosamples were collected from more than 600 participants, this number may be too low for (sub) stratification of the data (e.g. insulin delivery modality, different treating centres and therapies etc.). - In the prospective group there was a relatively high dropout rate of 25% after 2 years, largely affected by the Covid-19 outbreak.